A stable Pharmaceutical composition for oral administration comprising 4 - amino - 1 - (2R, 5S) - 2 - (hydroxymethyl) - 1,3 - oxatiolan - 5 - yl - 1.2 - dihydropyrimidine - 2 - ona, acid ({(2R) - 1 - (6 - amino - 9h purine 9 - il) propan-2-yl oxy methyl) Phosphoric acid and 8 - Chloro - 5 - (cyclopropylethynyl) - 5 - (trifluoromethyl) - 4 - azabici oxa - 2 -

摘要

A stable Pharmaceutical composition for oral administration in the form of a single dosage unit which comprises a nucleoside reverse transcriptase inhibitor, a nucleotide reverse transcriptase inhibitor, a reverse transcriptase inhibitor and one not nucleosu00eddico Or more pharmaceutically acceptable excipients.A method for Manufacturing a multigranulado coated tablet. The use of Combination of 4 - amino - 1 - [(2R, 5S) - 2 - (hydroxymethyl) - 1,3 - oxatiolan - 5 - yl] - 1.2 - dihydropyrimidine - 2 - ona, acid ({[(2R) - 1 - (6 - amino - 9h purine - 9 - il) propan-2-yl] oxy] methyl) Phosphoric acid and 8 - Chloro - 5 - (cyclopropylethynyl) - 5 - (trifluoromethyl) - 4 - oxa - 2-azabicyclo [4.4.Deca 7,9,11 - 0] - 3-one triennium 2008-2010 for the manufacture of a Medicament for the treatment of Viral Infections, particularly retroviral infections including human immunodeficiency virus (HIV) or prevention of symptoms or effects of an HIV infection or a result of it, and N an infected individual. A method of treatment used.